NGVB Logo

Reagent


Add to Cart
Reagent Information
Name Ad-mCMV-TK 
Reagent Type Vector 
Vector
Classifications
Adenovirus
Keywords
 
Cell Line Origin  
Short Description  
Long Description This replication-defective, first generation adenoviral vector is based on human adenovirus serotype 5, with deletions in its E1a and E3 viral encoding regions. This vector encodes the transgene for Herpes Simplex Type 1 thymidine kinase under the control of the murine cytomegalovirus (mCMV) promoter. The TK transgene was subcloned into the first generation adenoviral shuttle plasmid pAL120 containing the mCMV promoter to make the plasmid pAL120-TK. The adenoviral vector genome plasmid pJM17 (Microbix) and pAL120-TK were co-transfected in 293 cells (Microbix) and the adenoviral vector Ad-mCMV-TK was rescued by homologous recombination. Ad-mCMV-TK underwent three successive rounds of plaque purification and then amplified on 293 cells. Ad-mCMV-TK was purified from the 293 cell lysate by cesium chloride purification followed by three rounds of dialysis in 10mM Tris, ph 8.0.  
Vector Map Ad-mCMV-TK.doc
Sequence  
Grade Research 
Depositor Cedars-Sinai Medical Center, Los Angeles, CA  
References 1. Dewey RA, Morrissey G, Cowsill CM, Stone D, Bolognani F, Dodd NJ, Southgate TD, Klatzmann D, Lassmann H, Castro MG, Löwenstein PR. Chronic brain inflammation and persistent herpes simplex virus 1 thymidine kinase expression in survivors of syngeneic glioma treated by adenovirus-mediated gene therapy: implications for clinical trials. Nature Medicine . 1999 Nov;5(11):1256-63. PMID: 10545991. 2. Gerdes CA, Castro MG, Löwenstein PR. Strong promoters are the key to highly efficient, noninflammatory and noncytotoxic adenoviral-mediated transgene delivery into the brain in vivo . Mol Ther. 2000 Oct;2(4):330-8 3. Appleby CE, Kingston PA, David A, Gerdes CA, Umaña P, Castro MG, Lowenstein PR, Heagerty AM. A novel combination of promoter and enhancers increases transgene expression in vascular smooth muscle cells in vitro and coronary arteries in vivo after adenovirus-mediated gene transfer . Gene Ther . 2003 Sep;10(18):1616-22. PMID: 12907954 4. King GD, Muhammad AK, Xiong W, Kroeger KM, Puntel M, Larocque D, Palmer D, Ng P, Lowenstein PR, Castro MG. High-capacity adenovirus vector-mediated anti-glioma gene therapy in the presence of systemic antiadenovirus immunity . J Virol. 2008 May;82(9):4680-4. PMID: 18287240 . 
Biosafety The Indiana University Vector Production Facility works with this line under BL-2 containment but the level of containment required of any cell line or vector is at the descretion of the investigator's Institutional Biosafety Committee that may require a different level of containment. 
Comments  
Storage  
Availability